https://www.selleckchem.com/products/ski-ii.html
Gene augmentation therapy based on subretinal delivery of Adeno-Associated Viral (AAV) vectors is proving to be highly efficient in treating several inherited retinal degenerations. However, due to potential complications and drawbacks posed by subretinal injections, there is a great impetus to find alternative methods of delivering the desired genetic inserts to the retina. One such method is an intravitreal delivery of the vector. Our aim was to evaluate the efficacy of two capsid modified vectors that are less susceptible to cellular
Curtir
Comentario
Compartilhar
